TMCnet News
Ansun Biopharma to Present at the Inaugural LifeSci Partners Private Company Virtual Summer SymposiumSAN DIEGO, July 29, 2020 (GLOBE NEWSWIRE) -- Ansun Biopharma, Inc., a clinical stage biopharmaceutical company, today announced it will participate in the LifeSci Partners Private Company Virtual Summer Symposium, taking place August 4-5, 2020. The company will deliver a corporate update to potential investors and strategic partners, among other various relevant audiences. The corporate update will cover recent and upcoming Company milestones, as well as detail clinical progress of the Company’s lead drug candidate, DAS181, a multi-mechanism recombinant sialidase protein being studied for its potential to treat patients with respiratory diseases including influenza, parainfluenza and COVID-19 by preventing viral entry into respiratory epithelial cells. In addition, for treating COVID-19, DAS181 can prevent and block cytokines such as TNF production and treat the underlying diseases caused by the virus infection.
LifeSci Partners is hosting its inaugural Private Healthcare Company Virtual Summer Symposium on August 4 and 5, 2020. The Symposium will feature presentations by executives from more than 130 private healthcare companies in both the biopharma and medical device sectors as well as panel discussions with healthcare industry leaders, venture capital and investment communities. The format will include 25-minute presentations from each participating company followed by a moderated question and answer segment. About Ansun Biopharma Ansun Contact: Media Contact:
|
||||||||||||||
